Serko sells US InterpIX assets, reaffirms FY26 guidance

Serko Limited announced on October 2, 2025, the completion of the sale of its InterpIX expense management assets in the US to CerebriAl, effective September 30, 2025. This divestment is part of Serko's strategy to simplify operations and concentrate on its core growth priorities, focusing on an open, connected platform for travel content and services. Proceeds from the sale will be received as royalties on revenues generated from InterpIX customers and are expected to result in a non-cash accounting loss of approximately $2 million, but positively impact ongoing earnings.

Following the divestment, Serko reaffirmed its FY26 guidance, originally provided on May 20, 2025. The company expects total income of $115m-$123m and total spend of $127m-$133m. Risks to achieving this guidance include macro-economic and geopolitical factors, as well as currency and ARPCRN movements. Serko will continue to operate its Zeno expense solution and expand partnerships with US payment and expense providers.

Additionally, a notification of cessation of securities indicated that 56,341 options and 151,984 restricted share units ceased on September 30, 2025, due to unmet or unachievable conditions. Following these changes, Serko’s issued capital comprises 124,600,150 ordinary fully paid foreign exempt NZX shares, 3,868 unquoted options, and 5,581,291 unquoted restricted share units.